{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:58:58Z","timestamp":1792025938130,"version":"4.4.0"},"reference-count":201,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nowadays, people have relaxed their vigilance against COVID-19 due to its declining infection numbers and attenuated virulence. However, COVID-19 still needs to be concern due to its emerging variants, the relaxation of restrictions as well as breakthrough infections. During the period of the COVID-19 infection, the imbalanced and hyper-responsive immune system plays a critical role in its pathogenesis. Macrophage Activation Syndrome (MAS) is a fatal complication of immune system disease, which is caused by the excessive activation and proliferation of macrophages and cytotoxic T cells (CTL). COVID-19-related hyperinflammation shares common clinical features with the above MAS symptoms, such as hypercytokinemia, hyperferritinemia, and coagulopathy. In MAS, immune exhaustion or defective anti-viral responses leads to the inadequate cytolytic capacity of CTL which contributes to prolonged interaction between CTL, APCs and macrophages. It is possible that the same process also occurred in COVID-19 patients, and further led to a cytokine storm confined to the lungs. It is associated with the poor prognosis of severe patients such as multiple organ failure and even death. The main difference of cytokine storm is that in COVID-19 pneumonia is mainly the specific damage of the lung, while in MAS is easy to develop into a systemic. The attractive therapeutic approach to prevent MAS in COVID-19 mainly includes antiviral, antibiotics, convalescent plasma (CP) therapy and hemadsorption, extensive immunosuppressive agents, and cytokine-targeted therapies. Here, we discuss the role of the therapeutic approaches mentioned above in the two diseases. And we found that the treatment effect of the same therapeutic approach is different.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1200289","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:13:48Z","timestamp":1688652828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19"],"prefix":"10.3389","volume":"14","author":[{"given":"Shunyao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teding","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13054-020-03062-7","article-title":"The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection","volume":"24","author":"Pons","year":"2020","journal-title":"Crit Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s43856-021-00048-6","article-title":"Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant","volume":"1","author":"Coutinho","year":"2021","journal-title":"Commun Med (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"n579","DOI":"10.1136\/bmj.n579","article-title":"Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study","volume":"372","author":"Challen","year":"2021","journal-title":"Bmj"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27653","article-title":"Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review","volume":"25","author":"Kannan","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination","volume":"325","author":"Edara","year":"2021","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by south African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134782","article-title":"Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications","volume":"21","author":"Allegra","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10050582","article-title":"Endothelial dysfunction and SARS-CoV-2 infection: association and therapeutic strategies","volume":"10","author":"Deng","year":"2021","journal-title":"Pathogens"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/TCRM.S195538","article-title":"Clinical management of Relapsed\/Refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies","volume":"17","author":"Yildiz","year":"2021","journal-title":"Ther Clin Risk Manage"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010206","article-title":"Detection and prediction of macrophage activation syndrome in still\u2019s disease","volume":"11","author":"Javaux","year":"2021","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.681875","article-title":"Macrophage activation syndrome in pediatric systemic lupus erythematosus: a systematic review of the diagnostic aspects","volume":"8","author":"Abdirakhmanova","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200361","article-title":"Is macrophage activation syndrome in Kawasaki disease underrecognized","volume":"48","author":"Natoli","year":"2021","journal-title":"J Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04965-6","article-title":"Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls","volume":"42","author":"Mert","year":"2022","journal-title":"Rheumatol Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00373-8","article-title":"Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study","volume":"10","author":"Ruiz-Antor\u00e1n","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41232-020-00131-w","article-title":"Macrophage activation syndrome and COVID-19","volume":"40","author":"Otsuka","year":"2020","journal-title":"Inflammation Regen."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"S\u00f6nmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217470","article-title":"Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3 hyper-responsiveness and risk for macrophage activation syndrome","volume":"80","author":"Schulert","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic lymphohistiocytosis","volume":"146","author":"Ponnatt","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121233","article-title":"Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome","volume":"40","author":"Strippoli","year":"2013","journal-title":"J Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3892\/etm.2021.10336","article-title":"Macrophage activation syndrome: a diagnostic challenge (Review)","volume":"22","author":"Bojan","year":"2021","journal-title":"Exp Ther Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30343-X","article-title":"Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study","volume":"2","author":"Webb","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30275-7","article-title":"COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study","volume":"2","author":"Manson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3201\/eid2609.202095","article-title":"Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, united states","volume":"26","author":"Martines","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03148-w","article-title":"Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia","volume":"590","author":"Grant","year":"2021","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102833","DOI":"10.1016\/j.ebiom.2020.102833","article-title":"Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients","volume":"57","author":"Wang","year":"2020","journal-title":"EBioMedicine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13144","article-title":"Cytokine storm syndrome in coronavirus disease 2019: a narrative review","volume":"289","author":"Gao","year":"2021","journal-title":"J Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2021.03.002","article-title":"COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome","volume":"232","author":"Ombrello","year":"2021","journal-title":"Transl Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.blre.2020.100743","article-title":"The looming storm: blood and cytokines in COVID-19","volume":"46","author":"Kaur","year":"2021","journal-title":"Blood Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"Elife"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201cCytokine storm\u201d relevant to COVID-19","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00571-1","article-title":"Immune cartography of macrophage activation syndrome in the COVID-19 era","volume":"17","author":"McGonagle","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12890-020-01343-z","article-title":"Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome","volume":"20","author":"Pandolfi","year":"2020","journal-title":"BMC Pulmonary Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.05.238188","article-title":"Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells","volume":"590","author":"Grant","year":"2020","journal-title":"bioRxiv"},{"key":"B63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","article-title":"Tissue-specific immunopathology in fatal COVID-19","volume":"203","author":"Dorward","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31057-6","article-title":"Is the HScore useful in COVID-19","volume":"395","author":"Leverenz","year":"2020","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"Hoenigl","year":"2022","journal-title":"Nat Microbiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.3390\/ijms23158606","article-title":"COVID-19 and the immune response: a multi-phasic approach to the treatment of COVID-19","volume":"23","author":"Sapir","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-021-00397-6","article-title":"The emergency use authorization of pharmaceuticals: history and utility during the COVID-19 pandemic","volume":"35","author":"Tran","year":"2021","journal-title":"Pharmaceut Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-021-00879-2","article-title":"What will be the role of molnupiravir in the treatment of COVID-19 infection","volume":"37","author":"Vitiello","year":"2021","journal-title":"Drugs Ther Perspect"},{"key":"B72","doi-asserted-by":"publisher","first-page":"m1610","DOI":"10.1136\/bmj.m1610","article-title":"Remdesivir in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"Bmj"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02482-2","article-title":"Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks","volume":"190","author":"Vitiello","year":"2021","journal-title":"Ir J Med Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin Infect Diseases."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13663","article-title":"CONVALESCENT plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence","volume":"51","author":"Kloypan","year":"2021","journal-title":"Eur J Clin Invest."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.02.008","article-title":"The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis","volume":"96","author":"Klassen","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4235\/agmr.22.0045","article-title":"Convalescent plasma in older adults with COVID-19: a systematic review and meta-analysis","volume":"26","author":"Aryana","year":"2022","journal-title":"Ann Geriatr Med Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3457","article-title":"Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"Cd013600","DOI":"10.1002\/14651858.CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review","volume":"5","author":"Valk","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1038\/s41467-021-25113-5","article-title":"Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors","volume":"12","author":"Kunze","year":"2021","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"152043","DOI":"10.1016\/j.semarthrit.2022.152043","article-title":"Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases-associated macrophage activation syndrome, a single center real-world analysis","volume":"55","author":"Chen","year":"2022","journal-title":"Semin Arthritis Rheumatism."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.7499\/j.issn.1008-8830.2110111","article-title":"Efficacy of plasma exchange in children with severe hemophagocytic syndrome: a prospective randomized controlled trial","volume":"24","author":"Yuan","year":"2022","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1136\/annrheumdis-2020-217390","article-title":"Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease","volume":"81","author":"Sato","year":"2022","journal-title":"Ann Rheumatic Diseases."},{"key":"B88","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13054-020-2836-4","article-title":"A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19","volume":"24","author":"Keith","year":"2020","journal-title":"Crit Care"},{"key":"B89","doi-asserted-by":"publisher","first-page":"106334","DOI":"10.1016\/j.ijantimicag.2021.106334","article-title":"Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial","volume":"57","author":"Faqihi","year":"2021","journal-title":"Int J Antimicrobial Agents."},{"key":"B90","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jha2.140","article-title":"Plasma exchange for COVID-19 thrombo-inflammatory disease","volume":"2","author":"Arulkumaran","year":"2021","journal-title":"eJHaem"},{"key":"B91","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s13054-020-03215-8","article-title":"Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study","volume":"24","author":"Gucyetmez","year":"2020","journal-title":"Crit Care"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.064","article-title":"Therapeutic plasma exchange in adults with severe COVID-19 infection","volume":"99","author":"Khamis","year":"2020","journal-title":"Int J Infect Diseases."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.07.001","article-title":"Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study","volume":"60","author":"Faqihi","year":"2020","journal-title":"J Crit Care"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2020.10.017","article-title":"Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)","volume":"27","author":"Hashemian","year":"2021","journal-title":"Pulmonology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.085","article-title":"Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19\u2013an exploratory study","volume":"102","author":"Jaiswal","year":"2021","journal-title":"Int J Infect Diseases."},{"key":"B96","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13054-020-03171-3","article-title":"Plasma exchange in critically ill COVID-19 patients","volume":"24","author":"Morath","year":"2020","journal-title":"Crit Care"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004613","article-title":"Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection","volume":"48","author":"Fernandez","year":"2020","journal-title":"Crit Care Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.06.014","article-title":"Benefits of plasma exchange on mortality in patients with COVID-19: a systematic review and meta-analysis","volume":"122","author":"Qin","year":"2022","journal-title":"Int J Infect Diseases."},{"key":"B99","doi-asserted-by":"publisher","first-page":"12786","DOI":"10.3390\/ijms222312786","article-title":"Therapeutic modulation of the host defense by hemoadsorption with CytoSorb&reg;&mdash;Basics, indications and Perspectives&mdash;A scoping review","volume":"22","author":"K\u00f6hler","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000865","article-title":"Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"22","author":"Jesudas","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10047-020-01244-2","article-title":"Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation","volume":"24","author":"Rademacher","year":"2021","journal-title":"J Artif Organs."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1159\/000517471","article-title":"Hemoperfusion with CytoSorb to manage multiorgan dysfunction in the spectrum of hemophagocytic lymphohistiocytosis syndrome in critically ill children","volume":"51","author":"Bottari","year":"2022","journal-title":"Blood Purif."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.925751","article-title":"Case report: cytokine hemoadsorption in a case of hemophagocytic lymphohistiocytosis secondary to extranodal NK\/T-cell lymphoma","volume":"9","author":"Ruiz-Rodr\u00edguez","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B104","doi-asserted-by":"publisher","first-page":"5539126","DOI":"10.1155\/2021\/5539126","article-title":"Hemoadsorption treatment with CytoSorb\u00ae in probable hemophagocytic lymphohistiocytosis: a role as adjunctive therapy","volume":"2021","author":"Ceruti","year":"2021","journal-title":"Case Rep Hematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-704552\/v1","article-title":"Effect of hemadsorption therapy in critically ill patients with COVID-19 (CYTOCOV-19): a prospective randomized controlled pilot trial","volume":"52","author":"Jarczak","year":"2022","journal-title":"Blood Purification"},{"key":"B106","doi-asserted-by":"publisher","first-page":"238","DOI":"10.46527\/2582-5038.238","article-title":"CytoSorb\u00ae in the treatment of severely-ill patient with post-COVID-19 complications: a case report","volume":"5","author":"Paul","year":"2022","journal-title":"Clin Case Rep Open Access."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines","year":"2022","journal-title":"Crit Care Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/children9050672","article-title":"Efficacy of anakinra on multiple coronary arteries aneurysms in an infant with recurrent Kawasaki disease, complicated by macrophage activation syndrome","volume":"9","author":"Bossi","year":"2022","journal-title":"Children"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914265","article-title":"Case report: baricitinib as an alternative in the maintenance therapy for macrophage activation syndrome secondary to nodular panniculitis","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06184-1","article-title":"Short-term, low-dose etoposide in refractory adult-onset still\u2019s disease-associated macrophage activation syndrome","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-021-03831-4","article-title":"Tapering doses of methylprednisolone pulse in the treatment of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"88","author":"Loganathan","year":"2021","journal-title":"Indian J Pediatrics."},{"key":"B112","doi-asserted-by":"publisher","first-page":"103492","DOI":"10.1016\/j.resp.2020.103492","article-title":"Pros and cons of corticosteroid therapy for COVID-19 patients","volume":"280","author":"Mattos-Silva","year":"2020","journal-title":"Respir Physiol Neurobiology."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PloS Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"Jama"},{"key":"B117","doi-asserted-by":"publisher","first-page":"174579","DOI":"10.1016\/j.ejphar.2021.174579","article-title":"Use of steroids in COVID-19 patients: a meta-analysis","volume":"914","author":"Thakur","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa865","article-title":"The right time for steroids in COVID-19","volume":"72","author":"Fern\u00e1ndez-Cruz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.200001261","article-title":"The importance of understanding the stages of COVID-19 in treatment and trials","volume":"23","author":"Griffin","year":"2021","journal-title":"AIDS Rev"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1901883","article-title":"The time to offer treatments for COVID-19","volume":"30","author":"Ngo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1618","article-title":"Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome","volume":"107","author":"Kuypers","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J Rheumatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset still\u2019s disease: an evidence-based review","volume":"14","author":"Zhou","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac133.162","article-title":"P163\u2003The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome","volume":"61","author":"Rajagopala","year":"2022","journal-title":"Rheumatology"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.02.005","article-title":"Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin","volume":"132","author":"Coca","year":"2009","journal-title":"Clin Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3164","article-title":"Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients","volume":"120","author":"Mahlaoui","year":"2007","journal-title":"Pediatrics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic lymphohistiocytosis","volume":"146","author":"Ponnatt","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2020.06.005","article-title":"Calcineurin inhibitors revisited: a new paradigm for COVID-19","volume":"24","author":"Hage","year":"2020","journal-title":"Braz J Infect Diseases."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2020.03.005","article-title":"Why choose cyclosporin a as first-line therapy in COVID-19 pneumonia","volume":"17","author":"Sanchez-Pernaute","year":"2021","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.327","article-title":"Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry","volume":"116","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Int J Infect Diseases."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PloS Pathog"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin a or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J Gen Virol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.08.001","article-title":"A novel In vitro CypD-mediated p53 aggregation assay suggests a model for mitochondrial permeability transition by chaperone systems","volume":"428","author":"Lebedev","year":"2016","journal-title":"J Mol Biol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nature03434","article-title":"Loss of cyclophilin d reveals a critical role for mitochondrial permeability transition in cell death","volume":"434","author":"Baines","year":"2005","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1053\/j.gastro.2020.11.045","article-title":"Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with covid-19: results from the ELITA\/ELTR multi-center European study","volume":"160","author":"Belli","year":"2021","journal-title":"Gastroenterology"},{"key":"B138","doi-asserted-by":"publisher","first-page":"108486","DOI":"10.1016\/j.clim.2020.108486","article-title":"Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients","volume":"217","author":"Urra","year":"2020","journal-title":"Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J Infect"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955523","article-title":"Macrophage activation syndrome in adults: characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen","volume":"13","author":"He","year":"2022","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10020-021-00308-0","article-title":"Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome","volume":"27","author":"Palmblad","year":"2021","journal-title":"Mol Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.3390\/molecules27144478","article-title":"Doxorubicin-based hybrid compounds as potential anticancer agents: a review","volume":"27","author":"Peter","year":"2022","journal-title":"Molecules"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16226","article-title":"Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults","volume":"132","author":"He","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"109826","DOI":"10.1016\/j.mehy.2020.109826","article-title":"Etoposide-based therapy for severe forms of COVID-19","volume":"142","author":"Hamizi","year":"2020","journal-title":"Med Hypotheses."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.006","article-title":"Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients","volume":"81","author":"MB","year":"2020","journal-title":"J Infect"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02888-9","article-title":"Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19","volume":"112","author":"Takami","year":"2020","journal-title":"Int J Hematol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/SHK.0000000000001231","article-title":"Etoposide and corticosteroid combination therapy improves acute respiratory distress syndrome in mice","volume":"52","author":"Aoyagi","year":"2019","journal-title":"Shock"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2665","article-title":"Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"19","author":"Imashuku","year":"2001","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Advances."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/annrheumdis-2022-eular.1637","article-title":"Pos1216 potential predictors of outcome for anakinra treatment in covid-19 patients with macrophage activation syndrome","volume":"81","author":"Amikishiyev","year":"2022","journal-title":"Ann Rheumatic Diseases."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03430-9","article-title":"Anakinra for the treatment of adult secondary HLH: a retrospective experience","volume":"116","author":"Naymagon","year":"2022","journal-title":"Int J Hematol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e21430","DOI":"10.7759\/cureus.21430","article-title":"Management of hepatitis a-induced macrophage activation syndrome with anakinra in systemic juvenile idiopathic arthritis: a case report","volume":"14","author":"AlNouwaiser","year":"2022","journal-title":"Cureus"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2022.8998","article-title":"Efficacy of anakinra treatment in pediatric rheumatic diseases: our single-center experience","volume":"37","author":"Demir","year":"2022","journal-title":"Arch Rheumatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B158","doi-asserted-by":"publisher","first-page":"109075","DOI":"10.1016\/j.intimp.2022.109075","article-title":"Current evidence on the use of anakinra in COVID-19","volume":"111","author":"Khani","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.894846","article-title":"Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06384-9","article-title":"Recurrent macrophage activation syndrome due to hyperimmunoglobulin d syndrome: a case-based review","volume":"42","author":"Gezgin Y\u0131ld\u0131r\u0131m","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30167-3","article-title":"Canakinumab in a subgroup of patients with COVID-19","volume":"2","author":"Ucciferri","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"21775","DOI":"10.1038\/s41598-020-78492-y","article-title":"Blockage of interleukin-1\u03b2 with canakinumab in patients with covid-19","volume":"10","author":"Landi","year":"2020","journal-title":"Sci Rep"},{"key":"B164","doi-asserted-by":"publisher","first-page":"495","DOI":"10.53854\/liim-2904-1","article-title":"Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review","volume":"29","author":"Koritala","year":"2021","journal-title":"Infez Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23451","article-title":"Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in covid-19 cardiac injury: the three c study)","volume":"43","author":"Sheng","year":"2020","journal-title":"Clin Cardiol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.03.011","article-title":"The effect of canakinumab on clinical outcomes in patients with COVID-19: a meta-analysis","volume":"84","author":"Ao","year":"2022","journal-title":"J Infect"},{"key":"B167","doi-asserted-by":"publisher","first-page":"155544","DOI":"10.1016\/j.cyto.2021.155544","article-title":"Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19","volume":"143","author":"Geng","year":"2021","journal-title":"Cytokine"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1899565","article-title":"Macrophage activation syndrome in patients with adult-onset still\u2019s disease under tocilizumab treatment: a single-center observational study","volume":"32","author":"Yamabe","year":"2022","journal-title":"Mod Rheumatol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1818961","article-title":"Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset still\u2019s disease with a previous successful tocilizumab treatment","volume":"5","author":"Naniwa","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"B173","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/annrheumdis-2022-eular.2275","article-title":"Op0194 combination anakinra and tocilizumab to treat refractory macrophage activation syndrome triggered by adult-onset still\u2019s disease","volume":"81","author":"Alveyn","year":"2022","journal-title":"Ann Rheumatic Diseases."},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15124","article-title":"Efficacy and safety of tocilizumab versus standard care\/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials","volume":"88","author":"Vela","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e2295","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev Med Virol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e2388","DOI":"10.1002\/rmv.2388","article-title":"Efficacy of tocilizumab in the treatment of COVID-19: an umbrella review","volume":"32","author":"Rezaei Tolzali","year":"2022","journal-title":"Rev Med Virol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02824-7","article-title":"Bacterial infections in patients hospitalized with COVID-19","volume":"17","author":"Moreno-Torres","year":"2022","journal-title":"Intern Emerg Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"Bmj"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/idr14030040","article-title":"Sarilumab administration in COVID-19 patients: literature review and considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect Dis Rep"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795315","article-title":"Immunotherapy of COVID-19: inside and beyond IL-6 signalling","volume":"13","author":"Zizzo","year":"2022","journal-title":"Front Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26589","article-title":"Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome","volume":"93","author":"Kerget","year":"2021","journal-title":"J Med Virol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheumatic Diseases."},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01236-2","article-title":"A case of XIAP deficiency successfully managed with tadekinig Alfa (rhIL-18BP)","volume":"42","author":"Geerlinks","year":"2022","journal-title":"J Clin Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cyto.2012.06.257","article-title":"P156 investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody","volume":"59","author":"Hatterer","year":"2012","journal-title":"Cytokine"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CART-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2022","journal-title":"Blood Adv"},{"key":"B186","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/annrheumdis-2022-eular.803","article-title":"Op0193 efficacy and safety of emapalumab, an anti-interferon gamma monoclonal antibody, in patients with macrophage activation syndrome (Mas) in systemic juvenile idiopathic arthritis (Sjia) who had failed high-dose glucocorticoids","volume":"81","author":"De Benedetti","year":"2022","journal-title":"Ann Rheumatic Diseases."},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_615_20","article-title":"Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and janus kinase inhibitors","volume":"53","author":"Cure","year":"2021","journal-title":"Indian J Pharmacol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.456","article-title":"COVID-19-associated secondary hemophagocytic lymphohistiocytosis requiring hematopoietic cell transplant","volume":"3","author":"Greenmyer","year":"2022","journal-title":"EJHaem"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211068840","article-title":"Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis","volume":"247","author":"Liu","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2022.21064","article-title":"Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset still\u2019s disease","volume":"9","author":"Levy","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.07.026","article-title":"Combined IFN-\u03b3 and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice","volume":"151","author":"Joly","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29026","article-title":"Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective","volume":"68","author":"Triebwasser","year":"2021","journal-title":"Pediatr Blood Cancer."},{"key":"B196","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cytogfr.2020.06.013","article-title":"The potential of JAK\/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19","volume":"54","author":"Goker Bagca","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0891-0","article-title":"The janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005682","article-title":"Randomized phase 3 trial of ruxolitinib for COVID-19-Associated acute respiratory distress syndrome","volume":"50","author":"Rein","year":"2022","journal-title":"Crit Care Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00044-3","article-title":"Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Han","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:13:57Z","timestamp":1688652837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":201,"alternative-id":["10.3389\/fimmu.2023.1200289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1200289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"article-number":"1200289"}}